AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu

doi:10.1186/s13045-015-0188-3

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

J Hematol Oncol. 2015 Aug 1:8:96. doi: 10.1186/s13045-015-0188-3.

Authors

Jingjing Wu¹, Jiaping Fu², Mingzhi Zhang¹, Delong Liu^{3

4}

Affiliations

¹ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
² Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
³ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. DELONG_LIU@NYMC.EDU.
⁴ Division of Hematology & Oncology, New York Medical College, Valhalla, NY, 10595, USA. DELONG_LIU@NYMC.EDU.

Abstract

Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Hodgkin Disease / drug therapy*
Humans
Immunotherapy / methods
Ki-1 Antigen
Killer Cells, Natural

Substances

Antibodies, Monoclonal
Ki-1 Antigen